A 6-Week, Randomized Study to Evaluate the Potential of CCP-020 (Diacerein 1%) Topical Ointment to Induce a Photoallergic Skin Reaction in Healthy Subjects, Using a Controlled Photopatch Test Design
Latest Information Update: 07 Feb 2020
At a glance
- Drugs Diacerein (Primary)
- Indications Bullous pemphigoid; Epidermolysis bullosa; Gout; Joint disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Castle Creek Pharmaceuticals
Most Recent Events
- 26 Mar 2018 New trial record